Galmed Pharmaceuticals Ltd
NASDAQ:GLMD
Galmed Pharmaceuticals Ltd
Research & Development
Galmed Pharmaceuticals Ltd
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Galmed Pharmaceuticals Ltd
NASDAQ:GLMD
|
Research & Development
-$3.9m
|
CAGR 3-Years
40%
|
CAGR 5-Years
31%
|
CAGR 10-Years
4%
|
|
|
Kamada Ltd
NASDAQ:KMDA
|
Research & Development
-$12.8m
|
CAGR 3-Years
2%
|
CAGR 5-Years
1%
|
CAGR 10-Years
2%
|
|
|
Enlivex Therapeutics Ltd
NASDAQ:ENLV
|
Research & Development
-$9.6m
|
CAGR 3-Years
19%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-2%
|
|
|
Urogen Pharma Ltd
NASDAQ:URGN
|
Research & Development
-$67.7m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
N/A
|
|
|
Entera Bio Ltd
NASDAQ:ENTX
|
Research & Development
-$5.5m
|
CAGR 3-Years
8%
|
CAGR 5-Years
5%
|
CAGR 10-Years
N/A
|
|
|
M
|
Matricelf Ltd
TASE:MTLF
|
Research & Development
-₪10.7m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Galmed Pharmaceuticals Ltd
Glance View
Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of oral therapy for the treatment of non-alcoholic steato-hepatitis (NASH). Arachmol, the main product of Galmed Pharmaceuticals, is a liver-targeted stearoyl-coenzyme A desaturase1 used in oral therapy for the treatment of NASH (Non-alcoholic Steatohepatitis).
See Also
What is Galmed Pharmaceuticals Ltd's Research & Development?
Research & Development
-3.9m
USD
Based on the financial report for Sep 30, 2025, Galmed Pharmaceuticals Ltd's Research & Development amounts to -3.9m USD.
What is Galmed Pharmaceuticals Ltd's Research & Development growth rate?
Research & Development CAGR 10Y
4%
Over the last year, the Research & Development growth was -27%. The average annual Research & Development growth rates for Galmed Pharmaceuticals Ltd have been 40% over the past three years , 31% over the past five years , and 4% over the past ten years .
